systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-406Research ArticleОБЗОРЫ / REVIEWSСочетание артериальной гипертонии и ишемической болезни сердца - проблема номер один современной кардиологической практикиThe association of arterial hypertension and ischemic heart disease is the main problem in modern cardiology practiceОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruДудаевВ. А.DudaevV. A.noemail@neicon.ruФоминаВ. М.FominaV. M.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России; ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияA.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation; I.M.Sechenov the First Moscow Medical University of the Ministry of Health of the Russian FederationRussian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииРоссияA.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian FederationRussian Federation2015231220221217075Copyright © Остроумова О.Д., Дудаев В.А., Фомина В.М., 20222022Остроумова О.Д., Дудаев В.А., Фомина В.М.Ostroumova O.D., Dudaev V.A., Fomina V.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/406

В статье приведены эпидемиологические данные, свидетельствующие о высокой частоте артериальной гипертонии (АГ) у больных с ишемической болезнью сердца (ИБС). Рассмотрены основные положения современных отечественных и зарубежных рекомендаций по лечению пациентов с сочетанием АГ и ИБС. Обсуждается целевой уровень артериального давления (АД) у этих больных. Рассмотрены приоритетные группы антигипертензивных препаратов, которые имеют преимущества при сочетании данных заболеваний. Особое внимание уделено проблеме вариабельности АД (ВАД) как нового фактора риска развития коронарных осложнений при АГ. Продемонстрированы возможности фиксированной комбинации периндоприла аргинин/амлодипин в снижении меж - и внутривизитной ВАД у лиц с АГ и ИБС в реальной клинической практике.

This article deals with the epidemiological datashowing higher frequency of arterial hypertension (AH) in patients with ischemic heart disease (IHD). We discussed the basic characteristics of modern domestic and foreign recommendations for treating patients with combination of AH and IHD. We showed the target of blood pressure (BP) in this category of patients. This article deals with the priority groups of antihypertensive drugs, which have the advantages in the combination usage in patients with association of these diseases. We fixed special attention to the problem of BP variability (BPV) as a new risk factor for the development of coronary complications in patients with AH. We showed the possibility of fixed combination of perindopril and amlodipine in reducing interand intervisit BPV in patients with AH and IHD in actual clinical practice.

артериальная гипертонияишемическая болезнь сердцавариабельность артериального давленияпериндоприламлоди- пинфиксированные комбинации антигипертензивных препаратовarterial hypertensionischemic heart diseaseblood pressure variabilityperindoprilamlodipinefixed-dose combinations of antihyper- tensive agentsReferencesShkolnikov V, McKee M, Leon D.A. Changes in life expectancy in Russia in the mid- 1990s. Lancet 2001; 357: 917-21.Shkolnikov V, McKee M, Leon D.A. Changes in life expectancy in Russia in the mid- 1990s. Lancet 2001; 357: 917-21.Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно - сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика. 2006; 2: 73-7.Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно - сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика. 2006; 2: 73-7.Bhatt D.L, Steg P.G, Ohman E.M. et al. REACH Registry Investigators. International pre - valence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.Bhatt D.L, Steg P.G, Ohman E.M. et al. REACH Registry Investigators. International pre - valence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Диагностика и лечение стабильной стенокардии (второй пересмотр). Кардиоваскулярная терапии и профилактика. 2008; 7 (6; Прил. 4): 3-40.Диагностика и лечение стабильной стенокардии (второй пересмотр). Кардиоваскулярная терапии и профилактика. 2008; 7 (6; Прил. 4): 3-40.Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP - Angina Treatment Pattern). Кардиология. 2003; 5: 9-15.Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP - Angina Treatment Pattern). Кардиология. 2003; 5: 9-15.Mancia G, Fagard R, Narkiewicz K. et al. ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2013; 31: 1281-357.Mancia G, Fagard R, Narkiewicz K. et al. ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2013; 31: 1281-357.The European Trial on reduction of cardiac events with Perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The European Trial on reduction of cardiac events with Perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Nissen S.E, Tuzcu E.M, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Nissen S.E, Tuzcu E.M, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.Poole-Wilson P.A, Lubsen J, Kirwan B.A. et al. Effect of long - acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.Poole-Wilson P.A, Lubsen J, Kirwan B.A. et al. Effect of long - acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.The PEACE Trial Investigators. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.The PEACE Trial Investigators. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.Messerli F.H, Mancia G, Conti C.R et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-93.Messerli F.H, Mancia G, Conti C.R et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-93.Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-9.Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-9.Bangalore S, Messerli F.H, Wun C et al. Treating to New Targets Steering Committee and Investigators. J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol 2009; 53: A217.Bangalore S, Messerli F.H, Wun C et al. Treating to New Targets Steering Committee and Investigators. J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol 2009; 53: A217.Bangalore S, Qin J, Sloan S et al. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122: 2142-51.Bangalore S, Qin J, Sloan S et al. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122: 2142-51.Mancia G, Messerli F, Bakris G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50: 299-305.Mancia G, Messerli F, Bakris G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50: 299-305.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-53.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-53.Pitt B, O’Neill B, Feldman R et al. QUIET Study Group. The Quinapril Ischemic Event Trial (QUIET) evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058-63.Pitt B, O’Neill B, Feldman R et al. QUIET Study Group. The Quinapril Ischemic Event Trial (QUIET) evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058-63.The PEАСЕ Trial Investigators. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.The PEАСЕ Trial Investigators. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.Rothwell P.M, Howard S.C, Dolan E et al. ASCOT-BPLA and MRC Trial Investigators. Effects of beta - blockers and calcium - channel blockers on within individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-80.Rothwell P.M, Howard S.C, Dolan E et al. ASCOT-BPLA and MRC Trial Investigators. Effects of beta - blockers and calcium - channel blockers on within individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-80.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366: 895-906.Oparil S. New challenges in blood pressure goal sandassessment. Nat Rev Cardiol 2011; 8: 74-5.Oparil S. New challenges in blood pressure goal sandassessment. Nat Rev Cardiol 2011; 8: 74-5.Muntner P, Shimbo D, Tonelli M et al. The relationship between visit - to - visit variability in systolic blood pressure and all - cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57: 160-6.Muntner P, Shimbo D, Tonelli M et al. The relationship between visit - to - visit variability in systolic blood pressure and all - cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57: 160-6.Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906-15.Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906-15.Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011, 42: 2860-5.Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011, 42: 2860-5.Кобалава Ж.Д., Котовская Ю.В., Лукьянова Е.А. от имени врачей - участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии с использованием фиксированной комбинации периндоприла аргинина/амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология. 2013; 6: 25-34.Кобалава Ж.Д., Котовская Ю.В., Лукьянова Е.А. от имени врачей - участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии с использованием фиксированной комбинации периндоприла аргинина/амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология. 2013; 6: 25-34.

The authors declare that there are no conflicts of interest present.